Breast cancer is the most common cancer in women. Breast cancer subtypes are classified according to histologic features, including morphology and receptor status. Information on the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2), as well as the proliferation index Ki67 (in early-stage disease), are relevant for clinical decisions. Molecular tests are now available to further classify the disease into subgroups, stratify risk or estimate the benefit of interventions. Some examples of such tests include the Recurrence Score (OncotypeDX), PAM50 (Prosigna), Mammaprint, Blueprint, and Breast Cancer Index (BCI), among others.
In recent years, the treatment of HR+HER2- breast cancer has been revolutionized by the introduction of the CDK4/6 inhibitors (CDK4/6i) palbociclib, ribociclib, and abemaciclib, the PI3 kinase inhibitor alpelisib, the antibody drug conjugates trastuzumab-deruxtecan and sacituzumab govitecan, the PARP inhibitor olaparib (when a germline BRCA 1 or 2 mutation is present) as well as the oral selective ER degrader elacestrant for patients with ESR1 mutations.
This Research Topic aims to widen the understanding of the advances in treatment for localized and metastatic HR+HER2- breast cancer to help improve the outcomes for patients. We welcome submissions on, but not limited to:
- Systemic treatment of metastatic HR+HER2- cancer.
- The next generation of PARP inhibitors
- Role of CDK4/6 inhibitors and new CDK inhibitors under evaluation
- Advances in targeting the PI3K-AKT-mTOR pathway
- The role and timing of systemic chemotherapy in early and late-stage HR+HER2- breast cancer
- Exploring molecular tests to direct care in early and late-stage HR+HER2- breast cancer.
- Opportunities to increase and decrease intensification of therapy for patients with early-stage HR+HER2- breast cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Breast cancer is the most common cancer in women. Breast cancer subtypes are classified according to histologic features, including morphology and receptor status. Information on the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2), as well as the proliferation index Ki67 (in early-stage disease), are relevant for clinical decisions. Molecular tests are now available to further classify the disease into subgroups, stratify risk or estimate the benefit of interventions. Some examples of such tests include the Recurrence Score (OncotypeDX), PAM50 (Prosigna), Mammaprint, Blueprint, and Breast Cancer Index (BCI), among others.
In recent years, the treatment of HR+HER2- breast cancer has been revolutionized by the introduction of the CDK4/6 inhibitors (CDK4/6i) palbociclib, ribociclib, and abemaciclib, the PI3 kinase inhibitor alpelisib, the antibody drug conjugates trastuzumab-deruxtecan and sacituzumab govitecan, the PARP inhibitor olaparib (when a germline BRCA 1 or 2 mutation is present) as well as the oral selective ER degrader elacestrant for patients with ESR1 mutations.
This Research Topic aims to widen the understanding of the advances in treatment for localized and metastatic HR+HER2- breast cancer to help improve the outcomes for patients. We welcome submissions on, but not limited to:
- Systemic treatment of metastatic HR+HER2- cancer.
- The next generation of PARP inhibitors
- Role of CDK4/6 inhibitors and new CDK inhibitors under evaluation
- Advances in targeting the PI3K-AKT-mTOR pathway
- The role and timing of systemic chemotherapy in early and late-stage HR+HER2- breast cancer
- Exploring molecular tests to direct care in early and late-stage HR+HER2- breast cancer.
- Opportunities to increase and decrease intensification of therapy for patients with early-stage HR+HER2- breast cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
